Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin’s lymphoma

Agrawal, Kanhaiyalal; Mittal, Bhagwant Rai; Bansal, Deepak; Varma, Neelam; Srinivasan, Radhika; Trehan, Amita; Kuruva, Manohar; Kashyap, Raghava; Bhattacharya, Anish; Marwaha, Ram Kumar

doi:10.1007/s12149-012-0665-5

Cited by 43 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of the false negative results in this study may be attributed to use of older generation PET/CT equipment [45]. The prevalence of BM invasion in advanced-stage HL was 16-18 % according to PET/CT and 3-6 % according to BMB [46,47]; among patients with early-stage HL and no B symptoms, the prevalence of BM invasion was less than 1 %.…”

Section: Staging Hodgkin Lymphomamentioning

confidence: 59%

Current status of FDG-PET/CT in staging of adult lymphoma

Biggi

Guerra

Hofman

2015

Clin Transl Imaging

View full text Add to dashboard Cite

Staging defines disease location and extent, suggests prognostic information and provides a baseline against which response or disease progression can be compared. Studies in Hodgkin (HL) and non-Hodgkin lymphoma (NHL) generally conclude that PET/CT is more accurate for diagnosing both nodal and extranodal disease than computed tomography (CT), thus having a strong potential impact on the staging of these lymphomas. Due to the high sensitivity and specificity of PET/CT in detecting bone marrow disease in newly diagnosed HL, bone marrow biopsy (BMB) is no longer indicated in HL; in aggressive NHL the detection of bone marrow involvement is still a topic of debate. In patients with a negative PET/CT, BMB is currently suggested to identify discordant histology, but its clinical role need to be further investigated. In indolent lymphoma FDG-PET enables staging the disease and characterization of intensity of glycolytic metabolism and this information provides additional prognostic information. In indolent lymphoma the pattern of marrow involvement is diffuse and PET/CT can be false negative in many cases. The main criteria to interpret staging PET/CT were reviewed. In 2014 were published the updated guidance on the evaluation, staging and response assessment of patients affected by HL and NHL and on the use of PET/ CT for staging and response assessment. The guidelines suggest that a reasonable approach would be omit the standard full dose contrast-enhanced CT (ceCT) if not already performed, and perform a low-dose non-enhanced PET/CT as a single imaging modality, with ceCT performed selectively determined by PET/CT findings.

show abstract

Section: Staging Hodgkin Lymphomamentioning

confidence: 59%

Current status of FDG-PET/CT in staging of adult lymphoma

Biggi

Guerra

Hofman

2015

Clin Transl Imaging

View full text Add to dashboard Cite

show abstract

“…Bone marrow biopsy is used for clinical staging decisions but obtains information from a limited area, typically the iliac crest. 18 F-FDG PET/CT provides information about the entire bone marrow, beyond clinical biopsy areas (Table 2) (35)(36)(37). Several authors reported that 18 F-FDG PET/CT accurately detected bone marrow involvement outside the pelvis in patients with negative results from routine biopsies of the iliac crest (35)(36)(37)(38) and have suggested that 18 F-FDG PET/CT can supplant marrow biopsy for purposes of staging.…”

Section: Initial Stagingmentioning

confidence: 99%

Value of¹⁸F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies

et al. 2015

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) understand the current status of the role of 18 F-FDG PET and PET/CT for staging and treatment monitoring of pediatric malignancies; (2) discuss the limitations of 18 F-FDG PET and PET/CT for pediatric cancer imaging; and (3) discuss areas of pediatric cancer imaging in which further studies are needed.

show abstract

“…In addition, in lymphoma, diffusely increased 18 F-FDG bone marrow uptake could be owing to inflammation rather than bone marrow involvement, and the reporting physician should be cautious in interpreting the diffuse pattern of uptake in this patient group. 88 …”

Section: Evaluation Of Skeletal Metastasesmentioning

confidence: 99%